Naason Newsletter 5/2025

Seoul and Osong, Republic of South Korea  September 29th, 2024 - Naason Science Inc. (Republic of South Korea), a preclinical contract, and collaborative, research organization announces the release of newly validated models for complete atro-ventricular block (CAVB) and pacemaker-induced cardiomyopathy (PICM). 

The models are available in both rodents (rats) and in pigs. The inclusion of these validated models is the product of 3 years of internal and collaborative research and development by Naason’s staff of scientists and technicians. The models are perfectly suited for the testing of new gene therapies as well as devices and drugs aimed at alleviating the underlying symptoms accompanied by these complex conditions. 

The models involve induction of the deficit, real-time ECG measurement, and subsequent telemetric tracking of ECG post-operatively and molecular and histopathological analysis. The porcine model includes all of the above with the additional possibility of echocardiography to track changes and to observe indications of efficacy.

For additional information please contact info@naasonscience.com

May 7, 2023 - Osong, Republic of South Korea; Edinburgh, United Kingdom

Naason Science Ltd. shows presence and support for those suffering from endometriosis by attending the World Congress of Endometriosis in Edinburgh, Scotland.

Women’s health and genitourinary health issues remain a largely unmet need on a global scale. Naason Science, its scientific and technical staff, along with its comprehensive preclinical drug development capabilities are committed to continued support for this community through preclinical research.

Recently in Edinburgh at the World Endometriosis Congress Naason Science attended workshops and presentations as well as chairing a session of presentations outlining some of the newer experimental drug treatments aimed at endometriosis.

Naason Science’s CEO Dr Larry Chong Park teamed up with Professor Christian Becker (Oxford University) to chair a session on potential new therapies for endometriosis. It was a great opportunity to hear the thoughts on what may be on the horizon for the treatment of endometriosis in the future. The presentations were thoroughly enjoyable and thought provoking.

While addressing the responses as well as the drug discovery community present during the sessions Dr Larry Park, Naason Science CEO said, “we are very happy to be able to receive and comment on the information provided by those presenting the data for these possible future therapies aimed at endometriosis. Despite my 25 years as a drug discoverer, I am always interested in how others see the route forward for certain technologies. It is obvious to us at Naason that the world endometriosis community is committed to finding new ways to tackle this potentially debilitating disease and this only makes Naason just as committed. Therefore, it is important that we remain in touch with developers as well as those advocating for increasing the amount of research and research funding into this disease area. The work that Naason continues to do the area of endometriosis is currently unmat5hced in the preclinical sector and we will increase this over the coming year.”

Naason science thanks all of the attendees with whom we met as well as all of those who presented their data and ideas at the WCE in Edinburgh.